CYP17A1 and metabolic syndrome: LDLC was the only factor observed to be decreased in both chromosomal sexes as a result of knocking out Cyp17a1. Low testosterone and estrogen parameters (E1–3) levels are predictive for the development of the metabolic syndrome and its consequence on CVD in men and women, respectively.